Peer-reviewed veterinary case report
Aluminum hydroxide lowers phosphate in cats with kidney disease
By Beita, Keren G et al.Ā·Published in American journal of veterinary researchĀ·2024Ā·Department of Small Animal Medicine and Surgery, United StatesĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Effect of aluminum hydroxide on serum phosphate and fibroblast growth factor 23 concentrations in young adult cats with surgically induced chronic kidney disease.
- Species:
- cat
Plain-English summary
A group of young adult cats with chronic kidney disease (CKD) were given aluminum hydroxide, a medication often used to lower phosphate levels, to see if it would help manage their condition. The cats were fed a special diet designed to limit phosphate intake, but the treatment did not significantly lower phosphate or fibroblast growth factor 23 (FGF-23) levels in the blood. While the control group showed an increase in FGF-23 over time, those receiving aluminum hydroxide did not experience this rise. Overall, the study found that aluminum hydroxide was not effective in reducing these levels in cats with CKD.
People also search for: cat chronic kidney disease treatment Ā· aluminum hydroxide for cats Ā· cat kidney disease phosphate levels
Abstract
OBJECTIVE: To describe serum fibroblast growth factor 23 (FGF-23) concentrations in young adult cats with remnant kidney model-induced chronic kidney disease (CKD) and to evaluate the effects of orally administered aluminum hydroxide (ALOH) on serum phosphate and FGF-23 concentrations in these cats. ANIMALS: 17 adult, purpose-bred cats with induced CKD and 13 healthy, age-matched cats. METHODS: A prospective, randomized study. Cats with induced CKD fed a wet renal diet received treatment with ALOH (90 mg/kg/d, PO) on days 0 to 42 and no treatment on days 43 to 84 (treatment group, n = 9) or no treatment on days 0 to 84 (control group, n = 8). Standard serum and urine biochemical analyses and several parameters reflective of calcium-phosphate balance, including serum parathyroid hormone and FGF-23 concentrations, were evaluated at baseline and various time points, including days 42 and 84. Age-matched, healthy, community-owned cats underwent similar evaluations at a single time point. Baseline data from CKD cats were compared to those of healthy cats. Longitudinal data from CKD cats were compared over time. RESULTS: Serum phosphate, total and ionized calcium, and FGF-23 concentrations were significantly higher in CKD cats at baseline relative to healthy cats (all P ≤ .009). Serum phosphate concentration did not change significantly over time in either CKD group; however, FGF-23 concentrations significantly increased over time in the control group (P < .02) but not the treatment group (P = .059). CLINICAL RELEVANCE: Aluminum hydroxide did not reduce serum phosphate or FGF-23 concentrations in this small study of cats with induced CKD chronically eating a phosphate-restricted diet.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39137806/